[저자] Agnieszka Lemanska, Colm Andrews, Louis Fisher, Ben Butler-Cole, Amir Mehrkar, Keith J Roberts, Ben Goldacre, Alex J Walker,
The OpenSAFELY Collaborative Membership of the OpenSAFELY Collaborative WalkerAlex J.MacKennaBrianInglesbyPeterRentschChristopher T.CurtisHelen J.MortonCaroline E.MorleyJessicaMehrkarAmirBaconSebHickmanGeorgeBatesChrisCrokerRichardEvansDavidWardTomCockburnJonathanDavySimonBhaskaranKrishnanSchultzeAnnaWilliamsonElizabeth J.HulmeWilliam J.McDonaldHelen I.TomlinsonLaurieMathurRohiniEggoRosalind M.WingKevinWongAngel Y. S.ForbesHarrietTazareJohnParryJohnHesterFrankHarperSamDouglasIan J.EvansStephen J. W.SmeethLiamGoldacreBen
¥
, Membership of the OpenSAFELY Collaborative WalkerAlex J.MacKennaBrianInglesbyPeterRentschChristopher T.CurtisHelen J.MortonCaroline E.MorleyJessicaMehrkarAmirBaconSebHickmanGeorgeBatesChrisCrokerRichardEvansDavidWardTomCockburnJonathanDavySimonBhaskaranKrishnanSchultzeAnnaWilliamsonElizabeth J.HulmeWilliam J.McDonaldHelen I.TomlinsonLaurieMathurRohiniEggoRosalind M.WingKevinWongAngel Y. S.ForbesHarrietTazareJohnParryJohnHesterFrankHarperSamDouglasIan J.EvansStephen J. W.SmeethLiamGoldacreBen
, Alex J. Walker, Brian MacKenna, Peter Inglesby, Christopher T. Rentsch, Helen J. Curtis, Caroline E. Morton, Jessica Morley, Amir Mehrkar, Seb Bacon, George Hickman, Chris Bates, Richard Croker, David Evans, Tom Ward, Jonathan Cockburn, Simon Davy, Krishnan Bhaskaran, Anna Schultze, Elizabeth J. Williamson, William J. Hulme, Helen I. McDonald, Laurie Tomlinson, Rohini Mathur, Rosalind M. Eggo, Kevin Wing, Angel Y. S. Wong, Harriet Forbes, John Tazare, John Parry, Frank Hester, Sam Harper, Ian J. Douglas, Stephen J. W. Evans, Liam Smeeth, Ben Goldacre, Brian MacKenna
[Category] update2024,
[Article Type] Article
[Source] PMC
Objectives Cancer treatments were variably disrupted during the COVID-19 pandemic. UK guidelines recommend pancreatic enzyme replacement therapy (PERT) to all people with unresectable pancreatic cancer. The aim was to investigate the impact of COVID-19 on PERT prescribing to people with unresectable pancreatic cancer and to investigate the national and regional rates from January 2015 to January 2023. Data sources With the approval of NHS England, we conducted this study using 24 million electronic healthcare records of people within the OpenSAFELY-TPP research platform. There were 22,860 people diagnosed with pancreatic cancer in the study cohort. We visualised the trends over time and modelled the effect of COVID-19 with the interrupted time series analysis. Conclusions In contrast to many other treatments, prescribing of PERT was not affected during the pandemic. Overall, since 2015, the rates increased steadily over time by 1% every year. The national rates ranged from 41% in 2015 to 48% in early 2023. There was substantial regional variation with the highest rates of 50% to 60% in West Midlands.
All Keywords
【저자키워드】 COVID-19, quality of care, Pancreatic cancer, Electronic healthcare records, pancreatic cancer enzyme replacement, pancreatic enzyme insufficiency, prescribing audit,